证券代码：301009 证券简称：可靠股份公告编号：2025-003 杭州可靠护理用品股份有限公司 第五届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 杭州可靠护理用品股份有限公司（以下简称"公司"或"本公司"）第五届 董事会第九次会议于 2025 年 4 月 24 日在浙江省杭州市余杭区向往街 1118 号英 国中心 T6-28 层公司会议室以通讯及现场表决相结合的方式召开，会议通知已于 2025 年 4 月 14 日以专人送达、电话及电子邮件等方式送达各位董事。本次会议 应出席董事 7 人（其中董事鲍佳女士以通讯方式审议表决），实际出席董事 7 人， 会议由董事长金利伟先生主持，公司监事及高级管理人员列席。会议召开符合有 关法律、法规、规章和《公司章程》的规定。 3、审议通过《关于<2024 年年度报告及其摘要>的议案》 《2024 年年度报告》及《2024 年年度报告摘要》具体内容详见公司同日披 露在巨潮资讯网（www.cninfo.com.cn）的相关公告。 该议案财务报告部分已经公司董事会审计委员会 ...

证券代码：301009 证券简称：可靠股份 公告编号：2025-008 特别提示： 1、公司拟定2024年度利润分配方案为：以实施2024年度利润分配方案时股 权登记日的总股本扣除公司回购专用证券账户中已回购股份后的总股本（公司现 有总股本271,860,000股扣除公司回购专用证券账户中的股份5,435,800股后的总 股本为266,424,200股）为基数，向全体股东每10股派发现金红利人民币0.70元（含 税），合计派发现金红利人民币18,649,694元，不送红股，不以资本公积金转增 股本，剩余未分配利润结转以后年度分配。 2、公司现金分红方案不涉及《深圳证券交易所创业板股票上市规则》第9.4 条相关规定的可能被实施其他风险警示情形。 一、审议程序 1、杭州可靠护理用品股份有限公司（以下简称"公司"）于2025年4月24日 分别召开了第五届董事会第九次会议、第五届监事会第八次会议，审议通过了《关 于2024年度利润分配预案的议案》。 2、本次利润分配预案尚需提交公司2024年度股东大会审议。 杭州可靠护理用品股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容 ...

国泰海通证券股份有限公司 二、保荐机构发现公司存在的问题及采取的措施 关于杭州可靠护理用品股份有限公司 2024 年度持续督导跟踪报告 | 保荐机构名称：国泰海通证券股份有限公司 | 被保荐公司简称：可靠股份 | | --- | --- | | 保荐代表人姓名：庞燎源 | 联系电话：010-83939239 | | 保荐代表人姓名：董冰冰 | 联系电话：010-83939742 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1、公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 不适用 | | 2、督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不限于防止 关联方占用公司资源的制度、募集资金管理制度、内控制 | 是 | | 度、内部审计制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3、募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 每月 1 次 | | （2）公司募集资金项目进展是否与信息披露 ...

目 录 一、内部控制审计报告…………………………………………第 1—2 页 内部控制审计报告 天健审〔2025〕6759 号 杭州可靠护理用品股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我 们审计了杭州可靠护理用品股份有限公司（以下简称可靠股份公司）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 二、注册会计师的责任 按照《企业内部控制基本规范》《企业内部控制应用指引》以及《企业内部 控制评价指引》的规定，建立健全和有效实施内部控制，并评价其有效性是可靠 股份董事会的责任。 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表 审计意见，并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于 情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低， 根据内部控制审计结果推测未来内部控制的有效性具有一定风险。 四、财务报告内部控制审计意见 我们认为，可靠股份公司于 2024 年 12 月 31 日按照《企业内部 ...

国泰海通证券股份有限公司 关于杭州可靠护理用品股份有限公司 2024 年度募集资金存放与使用情况的核查意见 国泰海通证券股份有限公司（以下简称"保荐机构"或"国泰海通"，曾用 名"国泰君安证券股份有限公司"）作为杭州可靠护理用品股份有限公司（以下 简称"可靠股份"或"公司"）首次公开发行股票并在创业板上市的保荐机构， 根据《证券发行上市保荐业务管理办法》《上市公司监管指引第 2 号——上市公 司募集资金管理和使用的监管要求》《深圳证券交易所创业板股票上市规则》《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等相 关法律、法规和规范性文件的规定，对可靠股份 2024 年度募集资金的存放与使 用情况进行了核查，具体情况如下： 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 根据中国证券监督管理委员会《关于同意杭州可靠护理用品股份有限公司首 次发行股票注册的批复》（证监许可〔2021〕1630 号），本公司由主承销商国泰海 通采用向战略投资者定向配售、网下向符合条件的投资者询价配售和网上向持有 深圳市场非限售 A 股股份或非限售存托凭证市值的社会公众投资者定价发行相 结合的方 ...

国泰海通证券股份有限公司 关于杭州可靠护理用品股份有限公司 首次公开发行股票并在创业板上市 之持续督导保荐总结报告书 经中国证券监督管理委员会《关于核准杭州可靠护理用品股份有限公司首次 公开发行股票的批复》（证监许可〔2021〕1630 号）核准，杭州可靠护理用品股 份有限公司（以下简称"可靠股份"、"发行人"、或"公司"）向社会公众公开发行 人民币普通股（A 股）股票 6,797.00 万股，发行价为人民币 12.54 元/股，股票发 行募集资金总额为 85,234.38 万元，扣除各项发行费用合计 9,078.90 万元，实际 募集资金净额为 76,155.48 万元。本次发行证券已于 2021 年 6 月 17 日在深圳证 券交易所（以下简称"深交所"）创业板上市。国泰海通证券股份有限公司（以 下简称"保荐机构"或"国泰海通"，曾用名"国泰君安证券股份有限公司"）担 任其持续督导保荐机构，持续督导期间至 2024 年 12 月 31 日。 目前，上述持续督导期已届满，国泰海通根据《证券发行上市保荐业务管理 办法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监 管指引第 2 号——创业 ...

国泰海通证券股份有限公司 关于杭州可靠护理用品股份有限公司部分募投项目结项 并将节余募集资金永久补充流动资金的核查意见 2、公司于 2024 年 4 月 26 日召开了第五届董事会第三次会议、第五届监事 会第三次会议，并经 2024 年 5 月 24 日召开的 2023 年度股东大会审议，通过了 《关于将部分募集资金永久补充流动资金、部分募集资金项目延期的议案》，同 意公司将"智能工厂建设项目"部分募集资金永久补充流动资金及其部分项目延 期至 2025 年 6 月 30 日之前支付，并将"技术研发中心升级建设项目"和"品牌 推广项目"募集资金项目延期。 三、本次结项的募投项目资金使用及节余情况 国泰海通证券股份有限公司（以下简称"保荐机构"或"国泰海通"，曾用 名"国泰君安证券股份有限公司"）作为杭州可靠护理用品股份有限公司（以下 简称"可靠股份"或"公司"）首次公开发行股票并在创业板上市的保荐机构， 根据《证券发行上市保荐业务管理办法》《上市公司监管指引第 2 号——上市公 司募集资金管理和使用的监管要求》《深圳证券交易所创业板股票上市规则》《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司 ...

目 录 | 一、审计报告……………………………………………………… 第 | 1—6 | 页 | | --- | --- | --- | | 二、财务报表……………………………………………………… 第 7—14 | | 页 | | （一）合并资产负债表…………………………………………… | 第 7 | 页 | | （二）母公司资产负债表………………………………………… | 第 8 | 页 | | （三）合并利润表………………………………………………… | 第 9 | 页 | | （四）母公司利润表………………………………………………第 | 10 | 页 | | （五）合并现金流量表……………………………………………第 | 11 | 页 | | （六）母公司现金流量表…………………………………………第 | 12 | 页 | | （七）合并所有者权益变动表……………………………………第 | 13 | 页 | | （八）母公司所有者权益变动表…………………………………第 | 14 | 页 | | | | 审 计 报 告 天健审〔2025〕6758 号 杭州可靠护理用品股份有限公司全体股东： 一、审计意见 我们审计了杭 ...

Financial Performance - The company's revenue for Q1 2025 was CNY 280,180,366.57, a decrease of 0.98% compared to CNY 282,967,455.35 in the same period last year[6] - Net profit attributable to shareholders was CNY 18,589,628.07, reflecting a 1.41% increase from CNY 18,331,987.65 year-on-year[6] - Basic earnings per share increased by 3.56% to CNY 0.0698, up from CNY 0.0674 in the same period last year[6] - Operating profit increased to ¥21,892,829.70, compared to ¥20,801,784.53 in the previous period, marking a growth of 5.24%[24] - Net profit for the current period is ¥18,614,887.13, slightly up from ¥18,204,327.14, representing an increase of 2.25%[25] Cash Flow - The net cash flow from operating activities surged by 112.42% to CNY 29,167,275.17, compared to CNY 13,731,198.53 in the previous year[12] - Cash received from sales and services was ¥267,053,603.28, down from ¥269,780,463.66, a decrease of 1.01%[27] - Net cash flow from operating activities was $29,167,275.17, an increase from $13,731,198.53 in the previous period, reflecting a positive trend in operational efficiency[28] - Total cash inflow from investment activities amounted to $112,033,319.66, significantly higher than $4,600,000.00 in the prior period, indicating strong investment recovery[28] - Cash outflow from investment activities was $8,585,517.35, down from $28,529,423.70, leading to a net cash flow from investment activities of $103,447,802.31, a substantial improvement[28] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,093,650,724.41, a slight increase of 0.20% from CNY 2,089,561,649.59 at the end of the previous year[6] - Total current assets increased to ¥1,292,528,954.09 from ¥1,275,660,793.30[19] - Total non-current assets decreased to ¥801,121,770.32 from ¥813,900,856.29[19] - Total liabilities increased, with short-term borrowings at ¥100,329,163.01[20] - Total liabilities decreased to ¥663,532,058.13 from ¥678,058,135.61, a reduction of 2.16%[24] Shareholder Information - Total number of common shareholders at the end of the reporting period is 16,358[15] - Major shareholder Jin Liwei holds 30.13% of shares, totaling 81,909,282 shares[15] - Major shareholder Bao Jia holds 29.13% of shares, totaling 79,190,682 shares[15] Research and Development - Research and development expenses rose by 15.34% to CNY 11,782,913.68, indicating a focus on innovation[12] - Research and development expenses rose to ¥11,782,913.68 from ¥10,215,780.02, an increase of 15.37%[24] Investment Income - The company reported a significant increase in investment income, reaching CNY 2,122,287.33, compared to a loss of CNY 885,966.04 in the previous year[12]

Financial Performance - The company's operating revenue for 2024 was ¥1,078,536,317.41, a decrease of 0.27% compared to ¥1,081,484,375.42 in 2023[26]. - Net profit attributable to shareholders for 2024 was ¥31,172,830.98, representing a significant increase of 54.44% from ¥20,184,911.13 in 2023[26]. - The net profit after deducting non-recurring gains and losses was ¥24,068,826.91, up 33.06% from ¥18,088,289.05 in 2023[26]. - The net cash flow from operating activities decreased by 76.97% to ¥52,441,537.27 from ¥227,702,913.25 in 2023[26]. - The total assets at the end of 2024 were ¥2,089,561,649.59, an increase of 4.90% from ¥1,992,017,074.35 at the end of 2023[26]. - Total revenue for 2024 was CNY 1,078,536,317.4, a slight decrease of 0.27% compared to CNY 1,081,484,375.4 in 2023[103]. - Adult incontinence products generated CNY 557,868,016.80, accounting for 51.72% of total revenue, down 1.33% year-over-year[103]. - Baby care products saw a revenue increase of 6.82%, reaching CNY 415,977,441.30, representing 38.57% of total revenue[103]. - Domestic sales increased by 2.66% to CNY 625,921,655.16, while overseas sales decreased by 4.06% to CNY 452,614,662.25[103]. Market Position and Strategy - The company is committed to becoming a world-class leader in the health care industry, with a focus on innovation and market expansion[5]. - The company is actively involved in research and development of new products and technologies to enhance its market position[5]. - The company is committed to expanding its market presence in the adult incontinence product sector to meet the growing demand from various consumer segments[39]. - The company ranked first in the domestic adult incontinence products market and its "Reliable" brand has been the top-selling product on e-commerce platforms for several consecutive years[42]. - The company has established a strong brand image in the disposable hygiene products market, focusing on adult incontinence care and elderly services[40]. - The company has a comprehensive sales model that includes both online and offline channels, partnering with major retailers like Walmart and leveraging e-commerce platforms such as Tmall and JD[63]. - The company is positioned to benefit from the increasing demand for elderly care services and products due to the aging population and supportive government policies[72]. Research and Development - The company holds a total of 251 authorized patents, including 63 invention patents, and has been involved in over 20 key research projects, enhancing its technological capabilities[43]. - The company is developing new products, including biodegradable hygiene products and high-absorption composite cores for diapers, which are expected to enhance product competitiveness[113]. - R&D investment amounted to ¥45,039,973.07 in 2024, representing 4.18% of operating revenue, an increase from 4.08% in 2023[113]. - The company aims to enhance its product structure and increase R&D investment to meet the growing demand in the aging population market[72]. Governance and Compliance - The company emphasizes the importance of accurate and complete financial reporting, with all board members present for the report's approval[7]. - The company has a complete governance structure, maintaining independence from its controlling shareholders in assets, personnel, finance, and operations[162]. - The board of directors consists of 7 members, including 3 independent directors, ensuring compliance with relevant regulations[157]. - The company has established independent financial decision-making and accounting practices[163]. - The company has a dedicated investor relations management strategy, fostering long-term relationships with investors[160]. - The company has implemented a "Quality and Return Dual Improvement" action plan, although details on its disclosure were not provided[153]. Employee and Management - The total number of employees at the end of the reporting period is 674, with 338 in the parent company and 336 in major subsidiaries[188]. - The company plans to implement various training programs in 2024, including EMBA courses, to enhance employee skills and align with strategic goals[190]. - The company has established a performance evaluation mechanism to enhance employee motivation and align organizational goals[189]. - Total compensation for directors, supervisors, and senior management in 2024 amounted to 7.6611 million yuan[178]. Challenges and Risks - The company faces increasing market competition and significant fluctuations in raw material prices, which pose risks to future development[8]. - The penetration rate of adult incontinence products in China is extremely low, estimated at less than 10%, compared to over 50% in Japan and the US[71]. - The company has acknowledged that changes in market conditions, such as declining birth rates, have impacted the efficiency of fund usage for the smart factory project[133]. Community Engagement and Social Responsibility - The company actively participated in community outreach and public welfare activities, enhancing brand recognition among target demographics[95]. - The company intends to enhance user engagement through offline promotions and community projects, building a valuable user operation system[142]. Future Outlook - Future guidance remains optimistic, with expectations for continued revenue growth, although exact figures were not provided[169]. - The company is committed to improving its operational efficiency and exploring new market opportunities as part of its long-term strategy[169].